Wet Macular Degeneration Pipeline Insights, 2019 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jan 25, 2019--The “Wet Macular Degeneration - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
“Wet Macular Degeneration - Pipeline Insight, 2019 report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Wet Macular Degeneration development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:Clinical Non-clinical Inactive: Discontinued and/or Dormant
Descriptive coverage of pipeline development activities for Wet Macular Degeneration
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Pipeline Therapeutics assessment of products for Wet Macular Degeneration
The report assesses the active Wet Macular Degeneration pipeline products by developmental stage, product type, molecule type, and administration route.
Scope of the reportThe report provides a snapshot of the pipeline development for the Wet Macular Degeneration The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Wet Macular Degeneration The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Wet Macular Degeneration The report also covers the dormant and discontinued pipeline projects related to the Wet Macular Degeneration
C ompanies Mentioned (Partial List)Aciont Inc. Adverum Biotechnologies Allergan Plc Alteogen Inc. Amakem NV Ampio Pharmaceuticals Apellis Pharmaceuticals Apexigen Applied Genetic Technologies Corporation Benitec Biopharma Limited Boehringer Ingelheim GmbH Cell Medica Limited Charlesson LLC. Cipla Ltd. Clanotech AB Clearside BioMedical Clonz Biotech Private Limited
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/fc62dd/wet_macular?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190125005425/en/
Laura Wood, Senior Press Manager
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Optical Disorders Drugs
INDUSTRY KEYWORD: HEALTH OPTICAL PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 01/25/2019 02:02 PM/DISC: 01/25/2019 02:01 PM